Abstract | BACKGROUND: RESULTS: A novel protein was produced by mutating the catalytic site of SpeB and the receptor binding surface of SpeA in a fusion of the two polypeptides. Vaccination of HLA-DQ8 transgenic mice with the SpeA-SpeB fusion protein protected against a challenge with the wild-type SpeA that was lethal to naïve controls, and vaccinated mice were protected from an otherwise lethal S. pyogenes infection. CONCLUSION: These results suggest that the genetically attenuated SpeA-SpeB fusion protein may be useful for controlling S. pyogenes infections. Vaccination with the SpeA-SpeB fusion protein described in this study may potentially result in protective immunity against multiple isolates of S. pyogenes due to the extensive antibody cross-reactivity previously observed among all sequence variants of SpeB and the high frequency of SpeA-producing strains.
|
Authors | Robert G Ulrich |
Journal | Journal of immune based therapies and vaccines
(J Immune Based Ther Vaccines)
Vol. 6
Pg. 8
(Oct 31 2008)
ISSN: 1476-8518 [Electronic] England |
PMID | 18976486
(Publication Type: Journal Article)
|